TopiVert and Onynx initiate clinical trials of NSKI drugs

UK-based biotechnology firm TopiVert has initiated clinical trials of two of its narrow spectrum kinase inhibitor (NSKI) drug candidates, TOP1288 and TOP1630, with support from contract research organisation (CRO) Onyx Scientific.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news